Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives

doi:10.12998/wjcc.v9.i13.2951

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 13

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9708)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

545

WORD

201

HTML

4114

Figures (1-1)

680

Tables (1-3)

630

Sum=6170

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

388

Download

1017

Sum=1405

Publishing Process of This Article

Item

Count

Browse

586

Download

1554

Sum=2140

May 6, 2021 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Clin Cases. May 6, 2021; 9(13): 2951-2968
Published online May 6, 2021. doi: 10.12998/wjcc.v9.i13.2951

Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives

Hung-Yuan Su, Yin-Chou Hsu

Hung-Yuan Su, Yin-Chou Hsu, Department of Emergency Medicine, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan

Hung-Yuan Su, Yin-Chou Hsu, School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung 82445, Taiwan

Author contributions: Hsu YC designed the study; Su HY and Hsu YC reviewed the literature and drafted the manuscript; both authors have read and approved the final manuscript.

Conflict-of-interest statement: Authors have nothing to declare.

Corresponding author: Hsu YC, MD, Staff Physician, Department of Emergency Medicine, E-DA Hospital, I-Shou University, No. 1 Yida Road, Jiao-su Village, Yanchao District, Kaohsiung 82445, Taiwan. yinchou0406@gmail.com

Received: January 4, 2021
Peer-review started: January 4, 2021
First decision: January 23, 2021
Revised: February 5, 2021
Accepted: March 25, 2021
Article in press: March 25, 2021
Published online: May 6, 2021
Processing time: 107 Days and 20 Hours

Core Tip

Core Tip: Several studies have addressed the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cirrhosis. The presence and stage of cirrhosis is correlated with the development of severe coronavirus disease-2019 (COVID-19), COVID-19-related adverse outcomes, and mortality. It remains unclear whether SARS-CoV-2 infection is a trigger of acute decompensation or acute-on-chronic liver failure in cirrhotic patients based on the current evidence. There is still no clearly proven effective pharmacological treatment for cirrhotic patients with COVID-19. Clinicians should maintain standard cirrhosis care, defer unnecessary liver-specific procedures and have a low threshold for admission if cirrhotic patients are infected with SARS-CoV-2.